20th International AIDS Conference - Melbourne, Australia


FRPL01 Where Are We Headed?
  Plenary Session
Venue: Plenary 2
Time: 25.07.2014, 08:10 - 10:30
Co-Chairs: Fábio Mesquita, Brazil
Lambert Grijns, Netherlands
Abby Landy, Australia

Webcast provided by International AIDS Society
08:10
FRPL0101
Powerpoint
CIPHER Grantees 2013
L. Bekker, South Africa

08:20
FRPL0102
Powerpoint
Award Presentation: CIPHER Grant Programme
F. Barré-Sinoussi, France

08:25
FRPL0103
How to Dance? - a film produced by Zvandiri, a group of HIV positive children & adolescents from Zimbabwe

08:30
FRPL0104
Where Are We Headed with ART?: Beyond an Undetectable Viral Load
D. Cooper, Australia

09:00
FRPL0105
Where Are We Headed with HIV and Adolescents?
L. Thomas Negrón, Puerto Rico

09:20
FRPL0106
Powerpoint
Where Are we Headed with HIV and Adolescents?
S. Kasedde, United States

09:50
FRPL0107
Powerpoint
Where Are We Headed on Ending HIV and AIDS in Children?
S. Essajee, United States

Powerpoints presentations
CIPHER Grantees 2013 - Linda-Gail Bekker
CIPHER Grantees 2013 - Linda-Gail Bekker
CIPHER Grantees 2013 - Linda-Gail Bekker
CIPHER Grantees 2013 - Linda-Gail Bekker

Award Presentation: CIPHER Grant Programme - Françoise Barré-Sinoussi
Award Presentation: CIPHER Grant Programme - Françoise Barré-Sinoussi

Where Are we Headed with HIV and Adolescents? - Susan Kasedde
Where Are we Headed with HIV and Adolescents? - Susan Kasedde

Where Are We Headed on Ending HIV and AIDS in Children? - Shaffiq Essajee



Rapporteur report

Track D report by Laura Ferguson


David Cooper provided an overview of the evolution of antiretroviral therapies and some ideas about future directions in therapy. He presented many compelling biomedical reasons for early treatment but noted that not all guidelines were concordant about when treatment should be initiated. Absent from the range of valid potential reasons put forward for this dissonance were social factors that might impede the early uptake of lifelong treatment. Cooper highlighted the need for ongoing implementation research to maximise uptake of all HIV-related services.

L’Orangelis Thomas Negron spoke about the similarity in life expectancy among people living with and without HIV but drew attention to some groups of PLHIV who might not fully enjoy this life expectancy such as those who experience gender-based violence and those without access to services. She highlighted the importance of the meaningful participation of adolescents in all aspects of the HIV response. She also noted that quality of life goes beyond access to antiretroviral therapy to also include access to other health and social services.

Susan Kasedde flagged adolescents as the only age-group among whom AIDS-related deaths are increasing. Kasedde stressed the need to invest more (and more effectively) in adolescents, to deliver better services and collect better data to inform these, to empower and engage adolescents and to accelerate an evidence- and rights-based response.  She acknowledged that, through a combination of laws and social judgment that constitute obstacles to healthy adolescent development we have created an environment that systematically fosters fear, violence and inequality that has to be changed. She presented a range of projects that have been successful in addressing the sexual and reproductive health and rights of adolescents as part of an effective HIV response.

Dispelling myths that are often used to justify inaction with regard to paediatric HIV, Shaffiq Essajee demonstrated that the knowledge and technologies to diagnose and treat children living with HIV now exist. Yet paediatric treatment coverage still lags behind that of adults. Essajee highlighted different points along the continuum of care where additional attention is required to address existing bottlenecks that limit the availability and uptake of services. Beyond health services, this included attention to the valuable role of community health workers as well as the need for broader links between communities and health services.

This session highlighted not only the biomedical advances that have been made in recent years but also some good implementation practices for addressing HIV across different populations. While there are undoubtedly some general good practices applicable to any aspect of an HIV response, the need to tailor investments and interventions to their target population came through in all of these presentations. Moving forward there is a need to increase our focus on implementation research so as to maximise learning about how to translate efficacy into real-world effectiveness, with appropriate attention to health systems as well as the social and cultural contexts within which these are situated.




   

    The organizers reserve the right to amend the programme.